EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cell-Impermeable Inhibitors Confirm That Intracellular Human Transglutaminase 2 Is Responsible for the Transglutaminase-Associated Cancer Phenotype

Eric W J Gates iD, Nicholas D Calvert iD, Nicholas J Cundy iD, Federica Brugnoli, Pauline Navals iD, Alexia Kirby, Nicoletta Bianchi iD, Gautam Adhikary, Adam J Shuhendler, Richard L Eckert, Jeffrey W Keillor iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241612546 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Eric W J Gates und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada. Hauptthemen laut MEDLINE: Protein Glutamine gamma Glutamyltransferase 2, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council, Canada Research Chairs, Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transglutaminase 2 (TG2) is a multifunctional enzyme primarily responsible for crosslinking proteins. Ubiquitously expressed in humans, TG2 can act either as a transamidase by crosslinking two substrates through formation of an Nε(ɣ-glutaminyl)lysine bond or as an intracellular G-protein. These discrete roles are tightly regulated by both allosteric and environmental stimuli and are associated with dramatic changes in the conformation of the enzyme. The pleiotropic nature of TG2 and multi-faceted activities have resulted in TG2 being implicated in numerous disease pathologies including celiac disease, fibrosis, and cancer. Targeted TG2 therapies have not been selective for subcellular localization, such that currently no tools exist to selectively target extracellular over intracellular TG2. Herein, we have designed novel TG2-selective inhibitors that are not only highly potent and irreversible, but also cell impermeable, targeting only extracellular TG2. We have also further derivatized the scaffold to develop probes that are intrinsically fluorescent or bear an alkyne handle, which target both intra- and extracellular TG2, in order to facilitate cellular labelling and pull-down assays. The fluorescent probes were internalized and imaged in cellulo, and provide the first implicit experimental evidence that by comparison with their cell-impermeable analogues, it is specifically intracellular TG2, and presumably its G-protein activity, that contributes to transglutaminase-associated cancer progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Glutamine gamma Glutamyltransferase 2NeoplasmsHumansTransglutaminasesFluorescent DyesPhenotype

Stichwörter der Autor:innen

cancercell impermeablechemical labelfluorescence microscopyfluorescent probeinhibitiontransglutaminase 2

Substanzen

Protein Glutamine gamma Glutamyltransferase 2TransglutaminasesFluorescent Dyes

Autor:innen und Institutionen

  • Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
  • Department of Translational Medicine, University of Ferrara, 44021 Ferrara, Italy.
  • Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

ORCID-Profile: Eric W J Gates, Nicholas D Calvert, Nicholas J Cundy, Pauline Navals, Nicoletta Bianchi, Jeffrey W Keillor

Förderung

  • Natural Sciences and Engineering Research Council
  • Canada Research Chairs
  • Natural Sciences and Engineering Research Council of Canada
  • Canada Research Chair Program

Zitieren

APA

Gates, E. W. J., Calvert, N. D., Cundy, N. J., Brugnoli, F., Navals, P., Kirby, A., Bianchi, N., Adhikary, G., Shuhendler, A. J., Eckert, R. L., & Keillor, J. W. (2023). Cell-Impermeable Inhibitors Confirm That Intracellular Human Transglutaminase 2 Is Responsible for the Transglutaminase-Associated Cancer Phenotype. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241612546

Vancouver

Gates EWJ, Calvert ND, Cundy NJ, Brugnoli F, Navals P, Kirby A, et al. Cell-Impermeable Inhibitors Confirm That Intracellular Human Transglutaminase 2 Is Responsible for the Transglutaminase-Associated Cancer Phenotype. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241612546

BibTeX
@article{Gates2023,
  author = {Gates, Eric W J and Calvert, Nicholas D and Cundy, Nicholas J and Brugnoli, Federica and Navals, Pauline and Kirby, Alexia and Bianchi, Nicoletta and Adhikary, Gautam and Shuhendler, Adam J and Eckert, Richard L and Keillor, Jeffrey W},
  title = {Cell-Impermeable Inhibitors Confirm That Intracellular Human Transglutaminase 2 Is Responsible for the Transglutaminase-Associated Cancer Phenotype},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241612546}
}
Kostenlos starten →